Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection



Status:Completed
Conditions:Influenza
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 64
Updated:4/21/2016
Start Date:February 2011
End Date:April 2014

Use our guide to learn which trials are right for you!

This study will serve to determine how influenza infection alters the bacterial colonization
patterns in the nasal and oropharyngeal compartments, and whether the immune response
correlate with these alterations. The investigators will be determining bacterial
composition and immune responses in the nose and oropharynx during influenza infection.

Specific Aims

Therefore, the overall aims of this study are as follows:

1. To identify baseline composition and kinetic changes in the nasal and oropharyngeal
microflora and immune responses after administering intranasal live attenuated
influenza virus (i.e., FluMist® vaccine) or saline mist to healthy subjects;

2. To identify nasal and oropharyngeal microbial composition and local immune responses
during influenza infections and after resolution of infection, and correlate these
changes with clinical outcomes.

Randomization and Post-Randomization Visits After undergoing the nasal swabs and
nasopharyngeal washes, and nasal epithelial brushing, healthy volunteers will be randomly
assigned to receive either saline nasal spray (placebo) or FluMist® nasal influenza vaccine
(live attenuated influenza vaccine, or LAIV). They will return 1-2 weeks and 4-6 weeks later
to repeat the nasal swabs and nasopharyngeal washes, and nasal epithelial brushings done at
the Enrollment Visit.

Samples will be processed to isolate 16s bacterial RNA and host RNA. 16s rRNA will be
analyzed by 16S sequencing for to determine the composition of the bacterial microbiome pre
and post LAIV or saline (placebo) administration. Host immune responses will be assessed
based upon microarray analysis of host RNA pre and post LAIV or saline administration.

Inclusion Criteria:

- Healthy volunteers:

- Healthy subjects between the ages of 18 and 65. Approximately half of the subjects
will be female and approximately half will be male.

- Must be eligible to receive live-attenuated nasal version of the influenza vaccine.

- Must be able to provide signed and dated informed consent.

- Healthy subjects willing and able to provide oropharyngeal and nasal cavity specimens

Exclusion Criteria:

- Immunosuppressive conditions or medications

- chronic systemic medical illness

- infections or antibiotic use within the past 60 days
We found this trial at
1
site
Los Angeles, California 90095
(310) 825-4321
UCLA UCLA's primary purpose as a public research university is the creation, dissemination, preservation and...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials